Targeting oncogenic lipids for cancer therapy

This technology describes methods and strategies for targeting oncogenic lipids for the treatment of cancer.

Unmet Need: Cancer therapeutics that avoid risk of treatment resistance

Many existing cancer treatments target oncogenic proteins resulting from metabolic dysregulation in cancer cells. However, these approaches commonly result in the development of treatment-resistant cells. Therapeutics that directly target metabolic pathways could potentially could avoid such risk of treatment resistance.

The Technology: Methods for targeting rewired metabolism in cancer cells

This technology describes approaches for targeting dysregulated metabolism found in cancer cells. By directly targeting the pathways that produce oncogenic lipids, this technology offers a therapeutic strategy that provides a higher therapeutic index, reduces the probability of treatment resistance, and has greater widespread applicability.

Applications:

• Cancer treatments
• Combination therapies with protein-targeting therapies
• Treatments for other conditions involving lipid dysregulation

Advantages:

• Higher therapeutic index
• Avoids risk of treatment resistance
• Widespread applicability

Lead Inventor:

Brent Stockwell, Ph.D.

Patent Information:

Patent Pending

Tech Ventures Reference:

• IR CU20221

• Licensing Contact: Beth Kauderer